Does State Medicaid Cover Fosamax (Alendronate)?

How Medicaid Formularies Work for Alendronate

Every state Medicaid program maintains a Preferred Drug List (PDL) that assigns drugs to cost-sharing tiers and attaches utilization-management rules. Generic alendronate entered the U.S. market in 2008 after Merck's patent on Fosamax expired, and its low acquisition cost pushed it onto preferred tiers in the vast majority of state PDLs [1]. Brand Fosamax, by contrast, carries a manufacturer list price near $80 per month and is frequently placed on a non-preferred tier or excluded outright unless a medical-necessity exception is approved [2].

The Centers for Medicare and Medicaid Services (CMS) requires states to cover "medically necessary" drugs but permits states wide latitude to manage formularies through prior authorization, step therapy, quantity limits, and therapeutic substitution [3]. That flexibility is why two neighboring states can have completely different access pathways for the exact same tablet.

For patients with postmenopausal osteoporosis, the American Association of Clinical Endocrinology 2020 guidelines list bisphosphonates including alendronate as first-line pharmacotherapy, citing their fracture-risk reduction data and cost-effectiveness [4]. Because alendronate occupies first-line status in major guidelines, most Medicaid medical directors have strong clinical justification to place the generic on a preferred tier with minimal barriers.

Physicians writing for Medicaid patients should confirm the specific state PDL before the prescription is sent. The Medicaid Drug Rebate Program requires manufacturers to pay rebates to states, and those rebates often make generic alendronate the lowest net-cost bisphosphonate available, reinforcing preferred status [5].

State-by-State Coverage Patterns

No two states are identical, but coverage tends to fall into three patterns. Generic alendronate is preferred with no prior authorization required in most states. Brand Fosamax is non-preferred with prior authorization required in roughly half of states. Brand Fosamax is excluded from the formulary, with only the generic covered, in a smaller but meaningful subset of states [3].

The FIT trial (Fracture Intervention Trial, N=2,027) demonstrated that alendronate 5 mg/day over 3 years reduced vertebral fracture risk by 47% (relative risk 0.53, P<0.001) compared with placebo in women with low femoral-neck bone-mineral density [6]. That level of evidence strengthens formulary inclusion arguments. A 1998 JAMA publication from FIT reported that alendronate reduced the risk of hip fracture by 51% and wrist fracture by 48% in the same population [6].

States that contract with managed care organizations (MCOs) add another layer. An MCO operating in Texas may have a tighter PDL than the state fee-for-service program, or vice versa. Patients enrolled in a Medicaid MCO should request that plan's specific drug list, not rely solely on the state agency's posted PDL [3].

The table below outlines a practical framework for checking coverage in any state:

1. Locate the state Medicaid agency website and search for "Preferred Drug List" or "Formulary."
2. Search for "alendronate" first, then "Fosamax." If the patient is in an MCO, request the MCO's formulary separately.
3. Note any "PA Required," "Step Therapy Required," or "Quantity Limit" flags.
4. If brand is denied, confirm whether generic fills the clinical need before initiating an appeal.

Prior-Authorization Criteria for Fosamax on Medicaid

Prior authorization (PA) for brand Fosamax on Medicaid typically requires the prescriber to document that the generic is clinically inappropriate for that patient. Accepted clinical rationales commonly include documented intolerance to tablet formulations, a swallowing disorder, esophageal motility problems, or a confirmed allergy to an excipient in the generic product [2].

The FDA-approved labeling for alendronate sodium specifies that patients must be able to stand or sit upright for at least 30 minutes after dosing and must have adequate renal function (creatinine clearance above 35 mL/min) [7]. Some state PA forms incorporate these contraindications directly, asking prescribers to attest that no listed contraindication is present and that the requested brand strength (10 mg daily or 70 mg weekly) matches the FDA-labeled indication.

Glucocorticoid-induced osteoporosis represents a common PA scenario. Patients on prednisone 7.5 mg/day or more for 3 or more months qualify for alendronate under its FDA-approved indication, and Medicaid PA reviewers generally accept documentation of steroid dose and duration as sufficient clinical evidence [7]. Providing that documentation up front reduces the rate of initial denials.

Average PA processing time under federal Medicaid rules is 3 business days for standard requests and 24 hours for expedited urgent requests [3]. If the plan does not respond within those windows, the request is deemed approved under CMS guidance, a point worth documenting in the chart.

The 2022 American College of Rheumatology guidelines for glucocorticoid-induced osteoporosis specifically state that "bisphosphonates are conditionally recommended as initial therapy for most patients starting long-term glucocorticoid therapy" [8]. Including that guideline citation in a PA letter meaningfully strengthens the request.

Step-Therapy Requirements Before Fosamax Is Approved

Step therapy means the plan requires a patient to try one or more preferred drugs before it will cover the requested agent. For alendronate, step therapy rarely applies to the generic itself. It most often applies when a prescriber requests brand Fosamax or a different bisphosphonate class (such as risedronate or ibandronate) without first documenting a trial of generic alendronate [2].

Typical step-therapy requirements, where they exist, ask for a documented 6-month or 12-month trial of generic alendronate at guideline-recommended doses (70 mg weekly for most osteoporosis indications) with either inadequate response (continued bone-density decline on dual-energy X-ray absorptiometry) or documented intolerance [4]. The National Osteoporosis Foundation notes that oral bisphosphonates, including alendronate, remain first-line choices precisely because the evidence base is larger than for most comparators [9].

Step therapy does not apply when a contraindication to alendronate exists. Severe renal impairment (creatinine clearance <35 mL/min) is a labeled contraindication that automatically exempts a patient from an alendronate step [7]. Documenting that contraindication in the PA request skips the step entirely and moves directly to approval or denial of the requested alternative.

Federal law under the Restoring the Patient's Voice Act (enacted as part of the Consolidated Appropriations Act 2021) strengthened step-therapy override rights for Medicare Advantage, but Medicaid step-therapy rules remain state-governed [3]. Some states have voluntarily adopted similar override criteria; others have not. Checking the state's specific managed-care contract language is the only reliable approach.

How to Appeal a Medicaid Denial of Fosamax

A denied Medicaid drug claim triggers specific appeal rights under federal law. Under 42 CFR 431.220, every state Medicaid program must provide enrollees a fair-hearing process, and decisions must be issued within 90 days (or 3 days for expedited appeals) [3]. The steps below apply in every state.

Step 1: Request an Internal Plan Reconsideration. Most MCOs must complete reconsideration within 30 days. Submit the prescriber's clinical notes, the most recent DXA scan result, any documented adverse effects of alternatives, and the relevant guideline citation (AACE 2020 [4] or ACR 2022 [8] both support bisphosphonate-first therapy).

Step 2: File a State Fair Hearing. If reconsideration fails, the patient or prescriber may file for a state fair hearing with the Medicaid agency. Under 42 CFR 431.221, requests must be filed within 90 days of the denial notice [3]. If the hearing request is filed before the denial's effective date, Medicaid must continue to provide the drug (or equivalent) during the appeal period.

Step 3: Seek External Review. Several states allow or require an independent external review of pharmacy denials. Check whether the state offers this pathway, because external reviewers are not bound by the plan's internal criteria and may apply a strict medical-necessity standard.

Step 4: Contact the State Medicaid Ombudsman. Every state has a Medicaid ombudsman or beneficiary assistance program that can help patients manage the process without legal representation. Contact information is typically posted on the state Medicaid agency website.

A well-documented appeal letter should include: the specific ICD-10 code (M81.0 for postmenopausal osteoporosis without fracture; M80.00 for osteoporosis with current pathological fracture), the T-score from the most recent DXA, fracture history, and the specific clinical reason the denied drug is preferred over covered alternatives [10]. Generic alendronate appeals are rare; brand Fosamax appeals succeed most often when a clear excipient intolerance or swallowing disorder is documented in the medical record.

Bone-Density Monitoring While on Medicaid Alendronate Coverage

Medicaid typically covers DXA scans for qualifying patients under HCPCS code G0130 or CPT 77080, subject to frequency limits. The U.S. Preventive Services Task Force recommends screening osteoporosis DXA for women 65 and older and for younger postmenopausal women with increased fracture risk [11]. Most state Medicaid programs follow this recommendation and cover at least one baseline DXA plus a repeat scan every 2 years for patients on pharmacotherapy.

Monitoring on alendronate follows specific clinical milestones. After 3 to 5 years of therapy, clinicians should reassess fracture risk to determine whether a "drug holiday" is appropriate [4]. The FLEX trial (N=1,099) showed that women who continued alendronate for 10 years versus stopping at 5 years had lower rates of clinical vertebral fracture (2.4% vs. 5.3%) but no significant difference in non-vertebral fracture rates [12]. That data supports selective continuation in high-risk patients rather than universal long-term use.

Atypical femoral fracture (AFF) is a rare but recognized complication of prolonged bisphosphonate use. The FDA updated the Fosamax label in 2011 to include AFF warnings, and Medicaid PA reviewers in some states will flag prescriptions exceeding 5 continuous years and request renewed justification [7]. Documenting the annual risk-benefit reassessment in the chart protects both the patient and the prescriber's PA record.

Cash-Pay and Manufacturer Savings Card Alternatives

When Medicaid denies brand Fosamax and the generic is not clinically suitable, several cost-reduction pathways exist outside the Medicaid benefit.

Generic alendronate 70 mg (4 tablets per month) has an average cash price near $15 at major pharmacy chains and $4 to $9 through discount programs such as GoodRx [2]. That price point is lower than most Medicaid cost-sharing amounts for non-preferred drugs, making cash payment a practical fallback for generic.

Manufacturer savings cards for brand Fosamax and its authorized generic are available from Organon (current U.S. marketer). Federal law prohibits manufacturer copay assistance cards from being used in conjunction with any federal health-care program, including Medicaid [3]. A patient who receives Medicaid cannot legally use a manufacturer card for a Medicaid-covered fill. However, if the patient chooses to pay entirely out of pocket for a drug not billed to Medicaid, the card may be used, though this arrangement requires explicit documentation and the patient must not submit the claim to Medicaid.

Patient assistance programs (PAPs) offered directly by manufacturers are a separate mechanism and do carry income thresholds. Organon's PAP accepts applications from patients below defined income limits regardless of insurance status. The prescribing office's social worker or the NeedyMeds database (needymeds.org) can help patients determine eligibility quickly [2].

Glucocorticoid-Induced Osteoporosis: A Higher-Priority Coverage Scenario

Patients on long-term systemic glucocorticoids represent a subgroup where Medicaid coverage of alendronate is especially important and generally more attainable. The FDA approved alendronate for glucocorticoid-induced osteoporosis prevention and treatment in both men and women [7], and the clinical urgency is well-supported by data.

The ACR 2022 guidelines for glucocorticoid-induced osteoporosis recommend initiating pharmacotherapy in patients with a 10-year major osteoporotic fracture probability of 10% or more on FRAX, or a T-score at or below -2.5 [8]. FRAX calculation is free at the WHO Fracture Risk Assessment Tool website (shef.ac.uk/FRAX), and printing the output for the PA file is a simple step that accelerates approval. Because glucocorticoid use is often documented through existing Medicaid pharmacy claims (prednisone, methylprednisolone), reviewers can frequently verify the clinical indication without requesting additional records.

In this population, a 70 mg weekly oral dose of alendronate is the standard starting point. For patients unable to tolerate oral formulations, intravenous zoledronic acid 5 mg once yearly is an alternative, though its Medicaid coverage pathway involves separate PA criteria and higher acquisition costs [4].

The Prescriber's Practical Checklist

Getting alendronate covered on Medicaid in any state comes down to a few consistent actions that take less than ten minutes at the point of care.

First, check the state PDL for "alendronate" before writing "Fosamax." Generic is almost always preferred. Second, if the patient truly needs brand or a different bisphosphonate, attach the DXA T-score, the ICD-10 code, the fracture history, and any documented intolerance to the PA request at submission. Third, include a one-sentence guideline citation: the AACE 2020 Clinical Practice Guidelines state that "oral bisphosphonates are recommended as first-line agents for reducing fracture risk in postmenopausal osteoporosis" [4]. Fourth, if the PA is denied, file the state fair-hearing request before the denial's effective date to preserve drug continuity during the appeal. Fifth, for cash-pay fallback, confirm the local generic alendronate price before counseling the patient; $15 per month is often cheaper than the Medicaid non-preferred copay.

A T-score of -2.5 or below at the femoral neck or lumbar spine is the diagnostic threshold for osteoporosis under WHO criteria and the standard trigger for pharmacotherapy initiation [10]. Documenting that specific number in the chart and the PA letter removes ambiguity for the reviewer.